A Study in Children and Teenagers to Learn if a TDV Dengue Vaccination Lowers the Chance of Hospital Stays for Dengue

Inclusion criteria

• ✓. The participant is a child or adolescent eligible to be vaccinated with TDV as part of a vaccination program planned in the study area.
• ✓. The participant's family do not intend to migrate away from the cohort hospital catchment area within 3 years of his/her enrollment into the study cohort.
• ✓. The participant's parent(s) or legally acceptable representative (LAR) signs and dates a written informed consent form (ICF), and any required privacy authorization where applicable, prior to the initiation of any study procedures, after the nature of the study has been explained according to local regulatory requirements.
• ✓. The participant signs and dates an age-appropriate assent form prior to the initiation of any study procedures, after the nature of the study has been explained according to local regulatory requirements.
• ✓. The participant's parent(s) or LAR agrees that a baseline blood sample may be taken from the participant.
• ✓. The participant is part of the cohort.
• ✓. The participant is hospitalized and clinically diagnosed with dengue.
• ✓. The participant has a blood sample available that was taken preferably within 5 days of fever onset and/or onset of symptoms compatible with dengue.